Skip to main content

Table 2 Different categories of treatment for S2-013 cell line

From: Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo

#

Group

n

Treatment

I

control

15

-

II

gemcitabine*

15

gemcitabine

III

gemcitabine/CoPP†

15

gemcitabine/CoPP

V

gemcitabine/DFO‡

15

gemcitabine/DFO

IV

gemcitabine/ZnPP†

15

gemcitabine/ZnPP

  1. * Gemcitabine (4 doses, 60 mg/kg per dose) on days 7, 10, 13 and 17.
  2. † CoPP, ZnPP (5 mg/kg per dose) or biliverdin (50 μmol/kg per dose) every alternative day from day 5 to day 17.
  3. ‡ DFO administration via an intraperitoneal osmotic pump (250 mg/kg per day for two weeks) from day 7 onwards.
Back to article page

Molecular Cancer

ISSN: 1476-4598